9926 Stock Overview
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Akeso, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$60.85 |
| 52 Week High | HK$78.75 |
| 52 Week Low | HK$26.45 |
| Beta | 0.54 |
| 1 Month Change | -16.93% |
| 3 Month Change | -7.10% |
| 1 Year Change | 45.05% |
| 3 Year Change | 79.50% |
| 5 Year Change | n/a |
| Change since IPO | 61.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9926 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.4% | -3.9% | -0.5% |
| 1Y | 45.1% | -5.7% | 19.9% |
Return vs Industry: 9926 exceeded the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 9926 exceeded the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 9926 volatility | |
|---|---|
| 9926 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9926 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9926's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,815 | Michelle Xia | www.akesobio.com |
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.
Akeso, Inc. Fundamentals Summary
| 9926 fundamental statistics | |
|---|---|
| Market cap | HK$54.62b |
| Earnings (TTM) | -HK$783.67m |
| Revenue (TTM) | HK$2.00b |
27.3x
P/S Ratio-69.7x
P/E RatioIs 9926 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9926 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.87b |
| Cost of Revenue | CN¥146.05m |
| Gross Profit | CN¥1.73b |
| Other Expenses | CN¥2.46b |
| Earnings | -CN¥735.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 92.21% |
| Net Profit Margin | -39.24% |
| Debt/Equity Ratio | 64.2% |
How did 9926 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 18:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akeso, Inc. is covered by 38 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yonglin Yan | BOCI Research Ltd. |
| Sharon Shi | BOCI Research Ltd. |
| Jiangqiao Tong | BOCI Research Ltd. |